Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Détail de l'auteur
Auteur Nadia TANEL |
Documents disponibles écrits par cet auteur (2)
Faire une suggestion Affiner la recherche
Immunization uptake in younger siblings of children with autism spectrum disorder / Ghassan Abu KUWAIK in Autism, 18-2 (February 2014)
[article]
Titre : Immunization uptake in younger siblings of children with autism spectrum disorder Type de document : Texte imprimé et/ou numérique Auteurs : Ghassan Abu KUWAIK, Auteur ; Wendy ROBERTS, Auteur ; Lonnie ZWAIGENBAUM, Auteur ; Susan E. BRYSON, Auteur ; Isabel M. SMITH, Auteur ; Peter SZATMARI, Auteur ; Bonnie M. MODI, Auteur ; Nadia TANEL, Auteur ; Jessica BRIAN, Auteur Article en page(s) : p.148-155 Langues : Anglais (eng) Mots-clés : autism autism spectrum disorder diphtheria-pertussis-tetanus-polioimmunization measles-mumps-rubella vaccine younger siblings Index. décimale : PER Périodiques Résumé : Background: Parental concerns persist that immunization increases the risk of autism spectrum disorder, resulting in the potential for reduced uptake by parents of younger siblings of children with autism spectrum disorder (“younger sibs”).Objective: To compare immunization uptake by parents for their younger child relative to their older child with autism spectrum disorder (“proband”) and controls.Design: Immunization status was obtained for 98 “younger sibs,” 98 “probands,” and 65 controls.Results: A significant group difference emerged for overall immunization status (Fisher’s exact test = 62.70, p .001). One or more immunizations in 59/98 younger sibs were delayed (47/98; 48%) or declined (12/98; 12.2%); immunizations were delayed in 16/98 probands (16.3%) and declined in only one. All controls were fully immunized, with only 6 (9.2%) delayed. Within the “younger sibs” group, 25/98 received an autism spectrum disorder diagnosis; 7 of whom (28%) were fully immunized. The rates of autism spectrum disorder diagnosis did not differ between immunized and nonimmunized younger sib groups, although small sample size limits interpretability of this result.Conclusion: Parents who already have one child with autism spectrum disorder may delay or decline immunization for their younger children, potentially placing them at increased risk of preventable infectious diseases. En ligne : http://dx.doi.org/10.1177/1362361312459111 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=224
in Autism > 18-2 (February 2014) . - p.148-155[article] Immunization uptake in younger siblings of children with autism spectrum disorder [Texte imprimé et/ou numérique] / Ghassan Abu KUWAIK, Auteur ; Wendy ROBERTS, Auteur ; Lonnie ZWAIGENBAUM, Auteur ; Susan E. BRYSON, Auteur ; Isabel M. SMITH, Auteur ; Peter SZATMARI, Auteur ; Bonnie M. MODI, Auteur ; Nadia TANEL, Auteur ; Jessica BRIAN, Auteur . - p.148-155.
Langues : Anglais (eng)
in Autism > 18-2 (February 2014) . - p.148-155
Mots-clés : autism autism spectrum disorder diphtheria-pertussis-tetanus-polioimmunization measles-mumps-rubella vaccine younger siblings Index. décimale : PER Périodiques Résumé : Background: Parental concerns persist that immunization increases the risk of autism spectrum disorder, resulting in the potential for reduced uptake by parents of younger siblings of children with autism spectrum disorder (“younger sibs”).Objective: To compare immunization uptake by parents for their younger child relative to their older child with autism spectrum disorder (“proband”) and controls.Design: Immunization status was obtained for 98 “younger sibs,” 98 “probands,” and 65 controls.Results: A significant group difference emerged for overall immunization status (Fisher’s exact test = 62.70, p .001). One or more immunizations in 59/98 younger sibs were delayed (47/98; 48%) or declined (12/98; 12.2%); immunizations were delayed in 16/98 probands (16.3%) and declined in only one. All controls were fully immunized, with only 6 (9.2%) delayed. Within the “younger sibs” group, 25/98 received an autism spectrum disorder diagnosis; 7 of whom (28%) were fully immunized. The rates of autism spectrum disorder diagnosis did not differ between immunized and nonimmunized younger sib groups, although small sample size limits interpretability of this result.Conclusion: Parents who already have one child with autism spectrum disorder may delay or decline immunization for their younger children, potentially placing them at increased risk of preventable infectious diseases. En ligne : http://dx.doi.org/10.1177/1362361312459111 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=224 Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial / Evdokia ANAGNOSTOU in Molecular Autism, (December 2012)
[article]
Titre : Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial Type de document : Texte imprimé et/ou numérique Auteurs : Evdokia ANAGNOSTOU, Auteur ; Latha V. SOORYA, Auteur ; William CHAPLIN, Auteur ; Jennifer BARTZ, Auteur ; Danielle B. HALPERN, Auteur ; Stacey WASSERMAN, Auteur ; A. Ting WANG, Auteur ; Lauren PEPA, Auteur ; Nadia TANEL, Auteur ; Azadeh KUSHKI, Auteur ; Eric HOLLANDER, Auteur Année de publication : 2012 Article en page(s) : 9 p. Langues : Anglais (eng) Mots-clés : Autism Adults Oxytocin Clinical trial Social cognition Index. décimale : PER Périodiques Résumé : BACKGROUND:There are no effective medications for the treatment of social cognition/function deficits in autism spectrum disorder (ASD), and adult intervention literature in this area is sparse. Emerging data from animal models and genetic association studies as well as early, single-dose intervention studies suggest that the oxytocin system may be a potential therapeutic target for social cognition/function deficits in ASD. The primary aim of this study was to examine the safety/therapeutic effects of intranasal oxytocin versus placebo in adults with ASD, with respect to the two core symptom domains of social cognition/functioning and repetitive behaviors.METHODS:This was a pilot, randomized, double-blind, placebo-controlled, parallel design trial of intranasal oxytocin versus placebo in 19 adults with ASD (16 males; 33.20 +/- 13.29 years). Subjects were randomized to 24 IU intranasal oxytocin or placebo in the morning and afternoon for 6 weeks. Measures of social function/cognition (the Diagnostic Analysis of Nonverbal Accuracy) and repetitive behaviors (Repetitive Behavior Scale Revised) were administered. Secondary measures included the Social Responsiveness Scale, Reading-the-Mind-in-the-Eyes Test and the Yale Brown Obsessive Compulsive Scale - compulsion subscale and quality of life (World Health Organization Quality of Life Questionnaire - emotional/social subscales). Full-information maximum-likelihood parameter estimates were obtained and tested using mixed-effects regression analyses.RESULTS:Although no significant changes were detected in the primary outcome measures after correcting for baseline differences, results suggested improvements after 6 weeks in measures of social cognition (Reading-the-Mind-in-the-Eyes Test, p = 0.002, d = 1.2), and quality of life (World Health Organization Quality of Life Questionnaire - emotion, p = 0.031, d = 0.84), both secondary measures. Oxytocin was well tolerated and no serious adverse effects were reported.CONCLUSIONS:This pilot study suggests that there is therapeutic potential to daily administration of intranasal oxytocin in adults with ASD and that larger and longer studies are warranted.TRIAL REGISTRATION:NCT00490802 En ligne : http://dx.doi.org/10.1186/2040-2392-3-16 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=202
in Molecular Autism > (December 2012) . - 9 p.[article] Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial [Texte imprimé et/ou numérique] / Evdokia ANAGNOSTOU, Auteur ; Latha V. SOORYA, Auteur ; William CHAPLIN, Auteur ; Jennifer BARTZ, Auteur ; Danielle B. HALPERN, Auteur ; Stacey WASSERMAN, Auteur ; A. Ting WANG, Auteur ; Lauren PEPA, Auteur ; Nadia TANEL, Auteur ; Azadeh KUSHKI, Auteur ; Eric HOLLANDER, Auteur . - 2012 . - 9 p.
Langues : Anglais (eng)
in Molecular Autism > (December 2012) . - 9 p.
Mots-clés : Autism Adults Oxytocin Clinical trial Social cognition Index. décimale : PER Périodiques Résumé : BACKGROUND:There are no effective medications for the treatment of social cognition/function deficits in autism spectrum disorder (ASD), and adult intervention literature in this area is sparse. Emerging data from animal models and genetic association studies as well as early, single-dose intervention studies suggest that the oxytocin system may be a potential therapeutic target for social cognition/function deficits in ASD. The primary aim of this study was to examine the safety/therapeutic effects of intranasal oxytocin versus placebo in adults with ASD, with respect to the two core symptom domains of social cognition/functioning and repetitive behaviors.METHODS:This was a pilot, randomized, double-blind, placebo-controlled, parallel design trial of intranasal oxytocin versus placebo in 19 adults with ASD (16 males; 33.20 +/- 13.29 years). Subjects were randomized to 24 IU intranasal oxytocin or placebo in the morning and afternoon for 6 weeks. Measures of social function/cognition (the Diagnostic Analysis of Nonverbal Accuracy) and repetitive behaviors (Repetitive Behavior Scale Revised) were administered. Secondary measures included the Social Responsiveness Scale, Reading-the-Mind-in-the-Eyes Test and the Yale Brown Obsessive Compulsive Scale - compulsion subscale and quality of life (World Health Organization Quality of Life Questionnaire - emotional/social subscales). Full-information maximum-likelihood parameter estimates were obtained and tested using mixed-effects regression analyses.RESULTS:Although no significant changes were detected in the primary outcome measures after correcting for baseline differences, results suggested improvements after 6 weeks in measures of social cognition (Reading-the-Mind-in-the-Eyes Test, p = 0.002, d = 1.2), and quality of life (World Health Organization Quality of Life Questionnaire - emotion, p = 0.031, d = 0.84), both secondary measures. Oxytocin was well tolerated and no serious adverse effects were reported.CONCLUSIONS:This pilot study suggests that there is therapeutic potential to daily administration of intranasal oxytocin in adults with ASD and that larger and longer studies are warranted.TRIAL REGISTRATION:NCT00490802 En ligne : http://dx.doi.org/10.1186/2040-2392-3-16 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=202